1. Academic Validation
  2. Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer

Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer

  • Am J Pathol. 2021 Jan;191(1):180-193. doi: 10.1016/j.ajpath.2020.10.005.
Zhaoting Yang 1 Chengye Zhang 2 Nan Che 1 Ying Feng 1 Chao Li 3 Yanhua Xuan 4
Affiliations

Affiliations

  • 1 Department of Pathology, Yanbian University Medicine College, Yanji, China; Institute for Regenerative Medicine, Yanbian University Medicine College, Yanji, China.
  • 2 Institute for Regenerative Medicine, Yanbian University Medicine College, Yanji, China; Air Force Medical Center of the Chinese People's Liberation Army, Beijing, China.
  • 3 Institute for Regenerative Medicine, Yanbian University Medicine College, Yanji, China.
  • 4 Department of Pathology, Yanbian University Medicine College, Yanji, China; Institute for Regenerative Medicine, Yanbian University Medicine College, Yanji, China. Electronic address: xuanyh1@ybu.edu.cn.
Abstract

Several studies have confirmed the function of Su(var)3-9, Enhancer of zeste, and Trithorax (SET) domain-containing 5 (SETD5) in post-translational modifications of nonhistone proteins. Mutation of the SETD5 gene has been implicated in the progression of many human cancers, such as breast Cancer (BC), but its functional role in BC progression is still unknown. The current article investigates the clinical significance and the functional role of SETD5 in BC. Our studies show that SETD5 expression in BC was related to poor clinical outcomes, including lymph node metastasis and advanced clinical stage. SETD5 expression positively correlated with tumor-associated macrophages. SETD5 was an independent predictor of poor overall survival in BC. Furthermore, these studies show that down-regulation of SETD5 significantly decreased BC cell proliferation, metastasis, and angiogenesis, and increased Apoptosis of BC cells. The mechanistic analysis showed that SETD5 contributes BC progression by interacting with Akt1 pathway. Also, in vivo experiments show that blocking of SETD5 expression significantly inhibited tumor growth and pulmonary metastasis of BC cells. These findings indicate that SETD5 is a potential prognosis marker and facilitates tumor progression of BC.

Figures
Products